Search results for "Vascularization"

showing 10 items of 519 documents

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

2010

Glioblastoma is a highly angiogenetic malignancy, the neoformed vessels of which are thought to arise by sprouting of pre-existing brain capillaries. The recent demonstration that a population of glioblastoma stem-like cells (GSCs) maintains glioblastomas indicates that the progeny of these cells may not be confined to the neural lineage. Normal neural stem cells are able to differentiate into functional endothelial cells. The connection between neural stem cells and the endothelial compartment seems to be critical in glioblastoma, where cancer stem cells closely interact with the vascular niche and promote angiogenesis through the release of vascular endothelial growth factor(VEGF) and str…

EndotheliumAngiogenesisTransplantation HeterologousSettore MED/27 - NEUROCHIRURGIAMice TransgenicMice SCIDBiologyModels BiologicalMiceVasculogenesisNeural Stem CellsMice Inbred NODCell Line TumormedicineAnimalsHumansCell LineageVasculogenic mimicryglioblastoma tumor vascularizationIn Situ Hybridization FluorescenceChromosome AberrationsMultidisciplinaryNeovascularization PathologicEndothelial CellsCell DifferentiationVascular endothelial growth factor BEndothelial stem cellVascular endothelial growth factor Amedicine.anatomical_structureVascular endothelial growth factor CTumor Markers BiologicalImmunologyCancer researchEndothelium VascularGlioblastomaNeoplasm TransplantationNature
researchProduct

Expression Profile of Endoglin in Different Grades of Endometrial Cancer

2019

Background Endoglin is a marker of active, proliferating endothelial cells of blood vessels. In many cancers, it is present in both peripheral vessels and vessels located inside the tumor. Endoglin is more specific and sensitive compared to other tumor angiogenesis markers. It is suggested that endoglin can be considered a reliable marker of disease outcome. Objective The aim of the study was to assess the expression of endoglin and to determine its potential usefulness as a complementary molecular marker of endometrial cancer. Method The study included 60 women who underwent hysterectomy: 45 with endometrioid endometrial cancer (study group) and 15 without neoplastic changes (control group…

Endotheliummedicine.drug_classAngiogenesisPharmaceutical ScienceReceptors Cell SurfaceMonoclonal antibodyMiceangiogenesisEndometrial cancerAntigens CDhemic and lymphatic diseasesBiomarkers Tumorotorhinolaryngologic diseasesmedicineAnimalsHumansmolecular markerendoglinNeovascularization Pathologicbusiness.industryEndometrial cancerCancerEndoglinmedicine.diseaseEndometrial Neoplasmsmedicine.anatomical_structureCase-Control StudiesCancer cellimmunohistochemistryCancer researchImmunohistochemistryFemaleEndothelium VascularNeoplasm Gradingbusinessvascular endotheliumSignal TransductionBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working …

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Epidemiologymedicine.medical_treatmentDiseaseFibromuscular dysplasia030204 cardiovascular system & hematology0302 clinical medicinefollow-up030212 general & internal medicineSocieties Medicalmedicine.diagnostic_test3. Good healthEuropeNatural historyTreatment OutcomeIN-STENT RESTENOSISCardiology030211 gastroenterology & hepatologyCardiology and Cardiovascular MedicineVascular Surgical Proceduresmedicine.medical_specialtyConsensusRevascularisationFIBROMUSCULAR DYSPLASIAINFRAINGUINAL VEIN BYPASSPhysical examinationRevascularizationSTENOSISrestenosis03 medical and health sciencesperipheral arterial diseaseInternal medicinemedicineHumansVELOCITY CRITERIAbusiness.industryNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseStenosisDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENT3121 General medicine internal medicine and other clinical medicineRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness030217 neurology & neurosurgeryFollow-Up StudiesEuropean Journal of Preventive Cardiology
researchProduct

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

2005

Colorectal cancer is the second most common malignant human neoplasia. Over recent years, many efforts have been performed in order to develop and improve therapeutic protocols, and many advances have been accomplished in both the field of adjuvant and palliative therapy. Most of the chemotherapic agents currently used in the clinical setting are the products of decades of research aimed at inhibiting the uncontrolled growth of dysplastic cells. However, new frontiers in this field have recently been opened, with the identification of key molecules involved in physiologic mechanisms that are of fundamental importance for cancer development and progression. Tumor-induced angiogenesis, the ca…

Epidermal Growth FactorNeovascularization PathologicAngiogenesisbusiness.industryColorectal cancerGrowth factormedicine.medical_treatmentAngiogenesis Inhibitorsmedicine.diseasePalliative TherapyNeovascularizationImmune systemCytokineOncologyImmune SystemImmunologymedicineCancer researchHumansPharmacology (medical)medicine.symptombusinessColorectal NeoplasmsAdjuvantSignal TransductionExpert review of anticancer therapy
researchProduct

Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion

2022

Osteosarcoma (OS) is the most common primary bone tumor mainly occurring in young adults and derived from primitive bone-forming mesenchyme. OS develops in an intricate tumor microenvironment (TME) where cellular function regulated by microRNAs (miRNAs) may affect communication between OS cells and the surrounding TME. Therefore, miRNAs are considered potential therapeutic targets in cancer and one of the goals of research is to accurately define a specific signature of a miRNAs, which could reflect the phenotype of a particular tumor, such as OS. Through NGS approach, we previously found a specific molecular profile of miRNAs in OS and discovered 8 novel miRNAs. Among these, we deepen our …

Epithelial-Mesenchymal TransitionQH301-705.5MAP Kinase Signaling SystemEMT proteinBone NeoplasmsArticleCatalysisCell LineInorganic ChemistryCell Line TumorHuman Umbilical Vein Endothelial CellsmetastasisHumansNeoplasm InvasivenessBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyOsteosarcomaOsteoblastsmicroRNANeovascularization PathologicOrganic ChemistryEMT proteinstumor angiogenesisGeneral MedicinemicroRNAsComputer Science ApplicationsGene Expression Regulation NeoplasticChemistryosteosarcoma; microRNAs; tumor angiogenesis; metastasis; EMT proteinsmetastasitumor angiogenesiInternational Journal of Molecular Sciences
researchProduct

Exposure to radial extracorporeal shockwaves induces muscle regeneration after muscle injury in a surgical rat model

2019

The leading cause of training interruption in sport is a muscle injury, for which the standard treatment is nonsteroidal anti-inflammatory drugs (NSAIDs). To find alternative treatments, we investigated whether the radial extracorporeal shockwave application (rESWT) could stimulate muscle regeneration. A lesion with complete rupture (grade III muscle tear) was set in the musculus rectus femoris of 12-week-old Wistar rats, and the NSAID diclofenac, rESWT, or a combined therapy were applied on day 0, 3, and 5 directly following the surgery. Rats were euthanized at 2, 4, and 7 days after surgery and the area of muscle lesion was excised for histological and gene expression analysis to determin…

Extracorporeal Shockwave TherapyMalemedicine.medical_specialty0206 medical engineeringMuscle Fibers SkeletalUrologyH&E stain610 MedizinNeovascularization Physiologic02 engineering and technologyMyoDExtracorporealLesion03 medical and health sciences0302 clinical medicineDiclofenacDownregulation and upregulation610 Medical sciencesMyosinmedicineAnimalsPaired Box Transcription FactorsRegenerationOrthopedics and Sports MedicineRats WistarMuscle SkeletalMyoD Protein030203 arthritis & rheumatologyWound Healingbusiness.industryStandard treatmentAnti-Inflammatory Agents Non-Steroidal020601 biomedical engineeringRatsAthletic Injuriesmedicine.symptombusinessmedicine.drug
researchProduct

Small-sized granules of biphasic bone substitutes support fast implant bed vascularization

2015

The present study investigated the influence of granule size of 2 biphasic bone substitutes (BoneCeramic® 400-700 μm and 500-1000 μm) on the induction of multinucleated giant cells (MNGCs) and implant bed vascularization in a subcutaneous implantation model in rats. Furthermore, degradation mechanisms and particle phagocytosis of both materials were examined by transmission electron microscopy (TEM). Both granule types induced tissue reactions involving primarily mononuclear cells and only small numbers of MNGCs. Higher numbers of MNGCs were detected in the group with small granules starting on day 30, while higher vascularization was observed only at day 10 in this group. TEM analysis reve…

Foreign-body giant cellPathologymedicine.medical_specialtyMaterials sciencebiphasic bone substitutePhagocytosisBiomedical EngineeringNeovascularization PhysiologicMedicine (miscellaneous)Giant CellsPeripheral blood mononuclear cellBone and BonesBiomaterialsMiceMultinucleatevascularizationMaterials TestingmedicineAnimalsParticle SizedegradationGranule (cell biology)granule sizephagocytosisGeneral MedicineRatsCell biologyDisease Models AnimalTransmission electron microscopyGiant cellBone SubstitutesLeukocytes MononuclearMicroscopy Electron ScanningBoneCeramicFemaleHydroxyapatitesImplantmultinucleated giant cellsResearch PaperBiomatter
researchProduct

A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology

2015

Bone morphogenetic proteins (BMPs), members of the TGF-β superfamily, have numerous biological activities including control of growth, differentiation, and vascular development. Using an in vitro co-culture endothelial cord formation assay, we investigated the role of a BMP7 variant (BMP7v) in VEGF, bFGF, and tumor-driven angiogenesis. BMP7v treatment led to disruption of neo-endothelial cord formation and regression of existing VEGF and bFGF cords in vitro. Using a series of tumor cell models capable of driving angiogenesis in vitro, BMP7v treatment completely blocked cord formation. Pre-treatment of endothelial cells with BMP7v significantly reduced their cord forming ability, indicating …

Genetics and Molecular Biology (all)MaleVascular Endothelial Growth Factor AFibroblast Growth FactorAngiogenesisBone Morphogenetic Protein 7Nudelcsh:MedicineSmad ProteinsFibroblast growth factorBiochemistryNeovascularizationMiceCell Movementlcsh:ScienceBMP7 Angiogenesis TumorTumorMultidisciplinaryCell DeathNeovascularization PathologicMedicine (all)Cell migrationCell biologyEndothelial stem cellSettore MED/26 - NEUROLOGIAVascular endothelial growth factor ADrug CombinationsAdipose TissueAdipose Tissue; Animals; Bone Morphogenetic Protein 7; Cell Death; Cell Line Tumor; Cell Movement; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Fibroblast Growth Factor 2; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Laminin; Male; Mice Nude; Neoplastic Stem Cells; Neovascularization Pathologic; Neovascularization Physiologic; Proteoglycans; Receptor Fibroblast Growth Factor Type 1; Signal Transduction; Smad Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Neoplastic Stem CellsFibroblast Growth Factor 2ProteoglycansCollagenmedicine.symptomReceptorType 1Research ArticleSignal TransductionMice NudeNeovascularization PhysiologicBMP7BiologyCell LineSettore MED/04 - PATOLOGIA GENERALECell Line TumormedicineHuman Umbilical Vein Endothelial CellsAnimalsHumansAgricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Receptor Fibroblast Growth Factor Type 1PhysiologicNeovascularizationCell ProliferationPathologicMatrigelBiochemistry Genetics and Molecular Biology (all)lcsh:REndothelial CellsKinase insert domain receptorVascular Endothelial Growth Factor Receptor-2Xenograft Model Antitumor AssaysAgricultural and Biological Sciences (all)lcsh:QAngiogenesisLamininGlioblastomaPLoS ONE
researchProduct

Antithrombotische Therapie nach peripherer Revaskularisation

2021

Was ist neu? Gerinnungshemmende Therapie nach peripherer Intervention In Analogie zur Koronarintervention wird nach Katheterinterventionen peripherer Gefäße meist passager eine duale Thrombozytenaggregationshemmung (TZAH) mit ASS 100 mg und Clopidogrel 75 mg durchgeführt. Größere Studien zu diesem Vorgehen fehlten bisher und die Empfehlungen der aktuellen Leitlinien haben den Charakter eines Expertenkonsens. Gerinnungshemmende Therapie nach peripherer Bypassoperation Nach peripherer Bypassanlage empfehlen die aktuellen Leitlinien in der Regel die Monotherapie mit einem TZAH (ASS 100 mg oder Clopidogrel 75 mg). In Einzelfällen wird bei venösen Bypässen eine orale Antikoagulation oder bei Kun…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicineEndovascular revascularizationbusiness.industryMedicine030212 general & internal medicineGeneral Medicine030204 cardiovascular system & hematologybusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

P29.02: Assessment of placental vascularization by three-dimensional power Doppler to evaluate effect of mifepristone vs. placebo in early pregnancy

2007

Gynecologymedicine.medical_specialtyRadiological and Ultrasound Technologybiologybusiness.industryObstetricsObstetrics and GynecologyEarly pregnancy factorGeneral MedicineMifepristonePlaceboPower dopplerReproductive Medicinebiology.proteinMedicineRadiology Nuclear Medicine and imagingbusinessPlacental vascularizationmedicine.drugUltrasound in Obstetrics and Gynecology
researchProduct